☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
AbbVie
AbbVie Receives EC’s Conditional Marketing for Tepkinly (Epcoritamab) to R/R Follicular Lymphoma (FL)
August 22, 2024
AbbVie’s Skyrizi (Risankizumab) Receives the EC’s Approval to Treat Moderate to Severe Active Ulcerative Colitis
July 26, 2024
AbbVie Reports the Regulatory Submissions to the US FDA and EMA of Rinvoq (Upadacitinib) to Treat Giant Cell Arteritis (GCA)
July 15, 2024
AbbVie’s Tepkinly (Epcoritamab) Gains the CHMP’s Positive Opinion to Treat R/R Follicular Lymphoma
July 1, 2024
AbbVie Reports the Acquisition of Celsius Therapeutics
June 28, 2024
AbbVie’s Epkinly (epcoritamab-bysp) Receives the US FDA’s Accelerated Approval to Treat R/R Follicular Lymphoma
June 27, 2024
Load more...
Back to Home